In the constantly expanding weight-loss medicine sector, pharmaceutical giants Eli Lilly and Novo Nordisk are competing fiercely. The focus of this debate is gradually turning from efficacy to availability in pharmacies, as both corporations struggle to meet the extraordinary demand for their respective medications. Eli Lilly’s Zepbound, which entered the U.S. market in December 2023, has swiftly captured a notable …